Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors
Status:
NOT_YET_RECRUITING
Trial end date:
2027-09-30
Target enrollment:
Participant gender:
Summary
This study will explore whether tirzepatide is a practical and acceptable treatment for postmenopausal women with a history of hormone receptor-positive breast cancer and obesity. The investigators aim to understand whether participants are willing and able to take this medication once weekly for 6 months and whether it may help improve weight and overall health. There will be monthly check-ins to monitor progress and safety. At the beginning and end of the study, participants will undergo body composition assessments, blood tests and a stool sample will be collected, and surveys will be completed.
Phase:
PHASE4
Details
Lead Sponsor:
Weill Medical College of Cornell University
Collaborator:
National Center for Advancing Translational Sciences (NCATS)